http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Congcong Huang (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Siqi Huang,Congcong Chen,Zhibo Zhao,Lingyi Jia,Yong Zhang 한국공업화학회 2023 Journal of Industrial and Engineering Chemistry Vol.118 No.-
In this work, hydroxyapatite (HAP) was in situ synthesized on coal fly ash (CFA) to prepare hydroxyapatitemodified coal fly ash composite aerogel (HCFAA). The maximum removal efficiency and capabilityof uranium(VI) on HCFAA were 97.6 % and 205.7 mg g1, respectively, which was much higher than thoseof CFA (83.6 % and 59.1 mg g1) (pH = 3.0, m/V = 1.0 g/L and T = 298 K). The desorption efficiency of uranium(VI) by HCFAA was even more than 80 % after five cycles, demonstrating that the introduction ofHAP had improved uranium(VI) removal performances. Pseudo-second-order and Langmuir models werefitted better with the experimental data, indicating the uranium(VI) removal process was a homogeneousmonolayer chemisorption. Meanwhile, the uranium(VI) removal efficiency for HCFAA in actual wastewaterwas higher to 80.6 % and uranium(VI) could even be completely separated from actual wastewaterby HCFAA during dynamic adsorption (m = 50 mg, V = 400 mL, C0 = 10 mg/L), further illustrating that theintroduction of HAP was an available method to modify CFA. Characterizations results demonstrated thaturanium(VI) was successfully immobilized on HCFAA through ion exchange, dissolution-precipitationand surface complexation. In conclusion, HCFAA was a prospective adsorbent for uranium(VI) separationin practical application.
-
Jianle Wang,Majid Nisar,Chongan Huang,Xiangxiang Pan,Dongdong Lin,Gang Zheng,Haiming Jin,Deheng Chen,Naifeng Tian,Qianyu Huang,Yue Duan,Yingzhao Yan,Ke Wang,Congcong Wu,Jianing Hu,Xiaolei Zhang,Xiangy 생화학분자생물학회 2018 Experimental and molecular medicine Vol.50 No.-
Oxidative stress-induced mitochondrial dysfunction is implicated in the pathogenesis of intervertebral disc degeneration (IVDD). Sirtuin 3 (SIRT3), a sirtuin family protein located in mitochondria, is essential for mitochondrial homeostasis; however, the role of SIRT3 in the process of IVDD has remained elusive. Here, we explored the expression of SIRT3 in IVDD in vivo and in vitro; we also explored the role of SIRT3 in senescence, apoptosis, and mitochondrial homeostasis under oxidative stress. We subsequently activated SIRT3 using honokiol to evaluate its therapeutic potential for IVDD. We assessed SIRT3 expression in degenerative nucleus pulposus (NP) tissues and oxidative stressinduced nucleus pulposus cells (NPCs). SIRT3 was knocked down by lentivirus and activated by honokiol to determine its role in oxidative stress-induced NPCs. The mechanism by which honokiol affected SIRT3 regulation was investigated in vitro, and the therapeutic potential of honokiol was assessed in vitro and in vivo. We found that the expression of SIRT3 decreased with IVDD, and SIRT3 knockdown reduced the tolerance of NPCs to oxidative stress. Honokiol (10 μM) improved the viability of NPCs under oxidative stress and promoted their properties of anti-oxidation, mitochondrial dynamics and mitophagy in a SIRT3-dependent manner. Furthermore, honokiol activated SIRT3 through the AMPKPGC- 1α signaling pathway. Moreover, honokiol treatment ameliorated IVDD in rats. Our study indicated that SIRT3 is involved in IVDD and showed the potential of the SIRT3 agonist honokiol for the treatment of IVDD.
-
Mengchao Ding,Xiaoying Kong,Weiyan Chen,Lei Yan,He Huang,Zunzhou Lv,Peng Jiang,Ali Mu,Congcong Huang,Jinsheng Shi 한국공업화학회 2022 Journal of Industrial and Engineering Chemistry Vol.110 No.-
Single cancer starvation therapy (ST) strategy can’t achieve satisfactory anti-tumor effect, mainly due tothe diversified nutritional sources of tumor cells. Herein, CuS@Axitinib-SiO2@2-Deoxy-D-glucose(2-DG)-CaCO3-RGD nanoparticles (CADCR NPs) were prepared for three-pathway blocking for efficient starvationtherapy as well as reinforced photothermal therapy (PTT) and chemodynamic therapy (CDT). AfterCADCR NPs were targeted to tumor cells, CaCO3 was ruptured in the acidic environment, releasingCa2+ to chelate glutamine and cutting off the glutamine metabolic pathway of the tumor. 2-DG was alsoreleased from mesoporous SiO2 and restrained the glycolytic pathway of tumor cells. In addition, underthe thermal stimulus of near-infrared irradiation, axitinib was released from CuS NPs, which inhibited theproliferation of tumor blood vessels, ultimately inhibiting the aerobic respiratory pathway of tumor cells. Interestingly, CADCR NPs also showed potential to reshape the tumor microenvironment (TME) and promotedthe transformation of macrophages from M2 to M1 type, increasing the expression of CD8+ T cellsin the tumor site. In conclusion, CADCR NPs achieve severe tumor starvation by simultaneously interferingwith three energy metabolic pathways, and further enhance tumor treatment with the aid of PTT,CDT, and TME improvement, which exhibits great potential for clinical cancer therapy.
-
Ting Xu,Xicheng Wang,Ying Xin,Zhenghang Wang,Jifang Gong,Xiaotian Zhang,Yanyan Li,Congcong Ji,Yu Sun,Feilong Zhao,Depei Huang,Yuezong Bai,Jian Li,Lin Shen 대한암학회 2023 Cancer Research and Treatment Vol.55 No.2
Purpose The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. HER2 amplification occurs in approximately 1% to 6% of colorectal cancer. In this study, we aimed to assess the efficacy and safety of trastuzumab in combination with chemotherapy in HER2-positive metastatic colorectal cancer (mCRC). Materials and Methods An open-label, phase II trial (Clinicaltrials.gov: NCT03185988) was designed to evaluate the antitumor activity of trastuzumab and chemotherapy in HER2-positive digestive cancers excluding gastric cancer in 2017. Patients from this trial with HER2-positive, KRAS/BRAF wild-type, unresectable mCRC were analyzed in this manuscript. Eligible patients were treated with trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and irinotecan (120 mg/m2 days 1 and 8 every 3 weeks). The primary endpoint was the objective response rate. Results Twenty-one HER2-positive mCRC patients were enrolled in this study. Seven patients (33.3%) achieved an objective res-ponse, and 11 patients (52.4%) had stable disease as their best response. The median progression-free survival (PFS) was 4.3 months (95% confidence interval, 2.7 to 5.9). Four of the 21 patients (19.0%) had grade 3 adverse events, including leukopenia, neutropenia, urinary tract infection, and diarrhea. No treatment-related death was reported. Exploratory analyses revealed that high tumor tissue HER2 copy number was associated with better therapeutic response and PFS. Alterations in the mitogen-activated protein kinase pathway, HER2 gene, phosphoinositide 3-kinase/AKT pathway, and cell cycle control genes were potential drivers of trastuzumab resistance in mCRC. Conclusion Trastuzumab combined with chemotherapy is a potentially effective and well-tolerated therapeutic regimen in mCRC with a high HER2 copy number.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
